Weight Management

What Is Retatrutide? Benefits, Trial Results and What to Know Before Starting

Retatrutide, an experimental triple-hormone medicine studied for weight loss

Retatrutide is an experimental weekly injection that copies three gut hormones. Early trials show some of the biggest weight loss seen with any medicine, but it isn’t approved anywhere yet.

If you follow weight-loss news, you’ve probably seen retatrutide come up more and more. Some people online call it “reta” or “Triple G,” and in our shop it’s listed as GLP-3 RTA. You may also see it called “GLP-3,” but that’s a nickname: there’s no hormone called GLP-3.

So what is retatrutide, what has the research found and what should you know before you even think about it?

Here’s a clear look at how it works, what the trials show so far and the questions worth asking first.

This page is for general education and isn’t medical advice. Retatrutide is still being tested and isn’t approved by the FDA or by BPOM in Indonesia. Products sold on this website are for lawful research use only.

Medical note: This page is educational and is not medical advice. Approved tirzepatide and semaglutide medicines are prescription-only. Products sold on this website are for lawful research use only.

What Is Retatrutide?

Retatrutide is a new medicine being developed by Eli Lilly, the company that makes tirzepatide (Mounjaro and Zepbound). In research papers, it’s also known by its code, LY3437943.

It’s a GIP, GLP-1 and glucagon receptor agonist. That means it copies three hormones your body already makes, which is why it’s often called a “triple agonist.” Like semaglutide and tirzepatide, it’s given as an injection once a week.

Retatrutide is in phase 3 trials, the last stage of testing before a company can ask for approval. Lilly has said it plans to apply to the FDA in early 2027. Until a regulator approves it, there’s no official label, no approved dose and no approved use.

How Retatrutide Works?

Your gut and pancreas release hormones that help control hunger, blood sugar and how your body uses energy. Retatrutide copies three of them at once.

How retatrutide works on the GLP-1, GIP and glucagon receptors

Together, those three actions can:

  • Make you feel full sooner and for longer
  • Quiet hunger signals in your brain
  • Slow how fast food leaves your stomach
  • Help your pancreas release insulin when your blood sugar is high
  • Raise the amount of energy your body burns
  • Help your body use stored fat for fuel

Here’s what each hormone adds.

GLP-1

Glucagon-like peptide-1 (GLP-1) slows digestion, helps release insulin after meals and tells your brain you’ve had enough to eat. It’s the same hormone that semaglutide copies on its own. If you’d like a closer look at that part of the process, see our guide to how semaglutide works.

GIP

Glucose-dependent insulinotropic polypeptide (GIP) adds to the insulin response and seems to strengthen the effect on appetite. Tirzepatide copies GIP and GLP-1 together. To see how that two-hormone approach works, read about how tirzepatide works.

Glucagon

This is what sets retatrutide apart. Glucagon normally raises blood sugar, but it also tells your body to burn more energy and break down fat, including fat stored in the liver.

On its own, glucagon would push blood sugar up. In retatrutide, the GLP-1 and GIP actions balance that out, so the overall effect is still lower blood sugar.

Retatrutide Trial Results: What the Research Shows?

Retatrutide has been tested in one large phase 2 trial and several phase 3 trials, called TRIUMPH. Most phase 3 results so far come from Lilly’s announcements, and some haven’t been published in full yet.

Researchers reviewing results from a retatrutide obesity clinical trial

The Phase 2 Trial

The first big results came in 2023, in the New England Journal of Medicine. The trial followed 338 adults with obesity for 48 weeks.

At the highest dose, people lost an average of 24.2% of their body weight, compared with 2.1% on a placebo. At the time, that was more than any weight-loss medicine had shown.

TRIUMPH-1: Adults With Obesity

TRIUMPH-1 is the main phase 3 trial in adults with obesity. Lilly shared the first results in May 2026, and the full results were published in the New England Journal of Medicine in September 2026.

After 80 weeks:

  • People on the highest dose lost an average of about 28% of their body weight
  • Close to half of them lost 30% or more
  • In a group with a higher starting weight who kept taking it for two years, average weight loss reached about 30%

TRIUMPH-2 and TRIUMPH-3: Diabetes and Heart Disease

These two trials looked at people with obesity who also had type 2 diabetes (TRIUMPH-2) or heart disease (TRIUMPH-3). Lilly shared the results in July 2026.

Weight loss was a little lower than in TRIUMPH-1, at up to about 21% in TRIUMPH-2 and about 23% in TRIUMPH-3 after 80 weeks. That’s common in these medicines: people with diabetes tend to lose less weight. In TRIUMPH-2, A1C (your average blood sugar over the past few months) also came down.

TRIUMPH-4: Obesity and Knee Pain

TRIUMPH-4 followed 445 adults with obesity and knee osteoarthritis for 68 weeks. People on the highest dose lost an average of 28.7% of their body weight, compared with 2.1% on a placebo.

Their knee pain also improved a lot, and some people reported no knee pain at all by the end of the trial.

Compared With Tirzepatide

These numbers are higher than what tirzepatide has shown in its own trials. But no completed trial has compared the two side by side yet, so it’s too early to say how much better retatrutide is. For what’s known so far, see retatrutide vs. tirzepatide.

Compared With Semaglutide

Semaglutide has the longest track record of the three, with years of real-world use and proven heart benefits. Retatrutide has shown more weight loss in trials, but it doesn’t have that history yet. You can read more in retatrutide vs. semaglutide.

Possible Benefits Beyond Weight Loss

Researchers are also looking at what retatrutide does for other health problems linked to weight. Early findings include:

  • Lower blood sugar and A1C in people with type 2 diabetes
  • Less knee pain in people with osteoarthritis
  • Large drops in liver fat in early studies
  • Improvements in blood pressure and waist size

What isn’t known yet is whether retatrutide lowers the risk of heart attack, stroke or other long-term problems. Those answers will take longer trials.

Side Effects Reported So Far

Retatrutide’s side effects look a lot like those of other GLP-1 medicines, but there are a few differences. They’re most common when people first start or when their dose goes up.

The most common side effects in trials have been:

  • Diarrhea (in up to about a third of people)
  • Nausea (in up to about 28% of people)
  • Constipation
  • Vomiting
  • Less appetite

Some people have also had dysesthesia, an unusual skin feeling such as tingling, burning or sensitivity to touch. In TRIUMPH-4, it affected up to about 1 in 5 people at the highest dose, compared with less than 1% on a placebo. It was usually mild.

More people stopped retatrutide because of side effects than stopped the placebo. In TRIUMPH-4, that was up to about 18% of people, compared with 4% on a placebo.

What to Know Before Starting Retatrutide

If you’re thinking about retatrutide, these are the points that matter most.

A doctor talking a patient through retatrutide before treatment

It Isn’t Approved Yet

Retatrutide isn’t approved by the FDA, by BPOM in Indonesia or by any other regulator. That means there’s no approved product, dose or label anywhere.

Right now, the only way to take it under proper medical care is in a clinical trial. Anything sold as retatrutide outside a trial hasn’t been checked by a regulator, so its contents, strength and purity can’t be guaranteed. [LINK WHEN LIVE: anchor “whether retatrutide is available in Indonesia” → /is-retatrutide-available-in-indonesia/]

The Long-Term Effects Aren’t Known

The longest trials so far have lasted about two years. Researchers still don’t know how retatrutide affects the heart over many years, how much of the weight lost is muscle or what happens after people stop.

With other medicines in this group, much of the weight tends to come back after stopping. It’s likely the same with retatrutide, but that hasn’t been fully studied.

It May Not Be Safe for Everyone

Because retatrutide has no label yet, there’s no official list of who shouldn’t take it. Trials of medicines like this one usually leave out people who are pregnant or breastfeeding, people who’ve had pancreatitis and people with a personal or family history of certain thyroid cancers.

That means there’s little or no safety information for those groups. If any of them apply to you, it’s even more important to talk to a doctor first.

It Works Best With Healthy Habits

In every trial, retatrutide was given along with advice on diet and exercise. Eating enough protein, staying active and getting good sleep help protect muscle and keep results going. No medicine replaces those habits.

Questions to Ask Your Doctor

Before you go further, it helps to bring a few questions to your appointment:

  • Am I a good candidate for a medicine like this?
  • Are there approved options, like semaglutide or tirzepatide, that would suit me?
  • Are there any retatrutide clinical trials I could join?
  • What side effects should I watch for, and how would we track my progress?
  • What’s the long-term plan if I stop?

Is Retatrutide Right for You?

Retatrutide looks promising, but it’s still an experimental medicine. For most people right now, the realistic choice is between approved medicines, lifestyle changes or joining a clinical trial.

Research papers and notes on metabolic health and obesity trials

The best next step is a conversation with a doctor who knows your health history. If you have questions in the meantime, you can contact us to discuss your goals.

Frequently Asked Questions

What is retatrutide?

Retatrutide is an experimental weekly injection made by Eli Lilly. It copies three hormones, GIP, GLP-1 and glucagon, which help control hunger, blood sugar and how much energy your body burns. It’s being tested for obesity and related conditions and isn’t approved yet.

Is retatrutide approved?

No. Retatrutide isn’t approved by the FDA, by BPOM in Indonesia or by any other regulator. It’s in phase 3 trials, and Lilly has said it plans to apply for FDA approval in early 2027.

How much weight do people lose on retatrutide?

In the phase 3 TRIUMPH-1 trial, people on the highest dose lost an average of about 28% of their body weight after 80 weeks. In TRIUMPH-4, people with obesity and knee osteoarthritis lost an average of 28.7% after 68 weeks.

What should I know before starting retatrutide?

Retatrutide isn’t approved, so there’s no official dose or label, and products sold outside clinical trials aren’t checked by a regulator. Its long-term effects are still unknown, and it can cause stomach side effects and unusual skin sensations. Talk to a doctor first.

What are the side effects of retatrutide?

The most common side effects in trials were diarrhea, nausea, constipation, vomiting and less appetite. Some people also had dysesthesia, an unusual skin feeling like tingling or burning. More people stopped retatrutide because of side effects than stopped a placebo.

How is retatrutide different from tirzepatide?

Tirzepatide copies two hormones, GIP and GLP-1, and is approved as Mounjaro and Zepbound. Retatrutide adds a third, glucagon, which raises the energy your body burns. It has shown more weight loss in its own trials, but it’s still experimental.

Is retatrutide the same as GLP-3?

“GLP-3” is a nickname some sellers use for retatrutide, but there’s no hormone called GLP-3. Retatrutide copies GIP, GLP-1 and glucagon. Its research code is LY3437943.

When will retatrutide be available?

Not yet. Lilly has said it plans to apply to the FDA in early 2027, and a review usually takes about a year. Approval in Indonesia would need a separate decision by BPOM.

Leave a Reply

Your email address will not be published. Required fields are marked *